Prelude Therapeutics Inc
No enriched coverage for $PRLD in the last 7 days.
No SEC Form 4 filings for $PRLD in the last 30 days.
See all $PRLD insider activity →Prelude Therapeutics (PRLD) will collaborate with Eli Lilly (LLY) to supply drugs for a Phase 1 breast cancer trial. The trial, set to begin in Q4 2026, will evaluate PRT13722 in combination with Lilly's abemaciclib and imlunestrant. Prelude's preclinical data shows efficacy and synergy in HR+/HER2- breast cancer models.
Analysts made several calls on Thursday. Goldman upgraded Sunbelt citing growth improvement. Wolfe reiterated Tesla as peer perform. Bernstein downgraded Palo Alto Networks, Okta, and SentinelOne due to valuation. Citizens upgraded JBHT to market outperform. Daiwa reiterated Nvidia as outperform but lowered its price target to $245. RBC initiated Kraft Heinz as outperform. Wells Fargo initiated several bitcoin miners as overweight. Barclays reinstated Paramount Skydance as underweight and Warner
Prelude Therapeutics (PRLD) received FDA clearance for its IND application for PRT13722, a KAT6A selective degrader, to treat HR+/HER2- breast cancer. The company plans to start a Phase 1 trial in Q4 2026. PRT13722 aims to improve efficacy and safety over existing therapies. PRLD's stock closed at $5.09, down 3.96%, and was at $5.10 in pre-market trading.
Recent PRLD coverage spans earnings, financial news and corporate actions.
The partnership validates Prelude's program and may boost its stock on positive trial outlook.
Biotech initiation can move the stock if traders treat the PT as a catalyst for positioning, but the article lacks trial-specific data.
Positive regulatory milestone may boost stock on trial initiation.
The IND clearance removes a major regulatory hurdle, allowing clinical enrollment and potentially unlocking future value.
Regulatory clearance adds credibility to pipeline.
AlphAI scores every news story that mentions PRLD with an AI model for sentiment and relevance, and aggregates insider trades from Prelude Therapeutics Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Prelude Therapeutics (PRLD) will collaborate with Eli Lilly (LLY) to supply drugs for a Phase 1 breast cancer trial. The trial, set to begin in Q4 2026, will evaluate PRT13722 in combination with Lilly's abemaciclib and imlunestrant. Prelude's preclinical data shows efficacy and synergy in HR+/HER2- breast cancer models.
2 min readAnalysts made several calls on Thursday. Goldman upgraded Sunbelt citing growth improvement. Wolfe reiterated Tesla as peer perform. Bernstein downgraded Palo Alto Networks, Okta, and SentinelOne due to valuation. Citizens upgraded JBHT to market outperform. Daiwa reiterated Nvidia as outperform but lowered its price target to $245. RBC initiated Kraft Heinz as outperform. Wells Fargo initiated several bitcoin miners as overweight. Barclays reinstated Paramount Skydance as underweight and Warner
6 min readPrelude Therapeutics (PRLD) received FDA clearance for its IND application for PRT13722, a KAT6A selective degrader, to treat HR+/HER2- breast cancer. The company plans to start a Phase 1 trial in Q4 2026. PRT13722 aims to improve efficacy and safety over existing therapies. PRLD's stock closed at $5.09, down 3.96%, and was at $5.10 in pre-market trading.
2 min readPrelude Therapeutics Inc (PRLD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader Phase 1 study of PRT13722 in patients with HR+ breast cancer anticipated to begin enrolling patients in the fourth
2 min readSeveral biotech stocks hit 52-week highs on August 21, 2026. Eloxx (ELOX) rose 16% to $23.40, reporting a Q2 net loss of $4.5M. argenX (ARGX) reached $1,058.69, with positive trial results for VYVGART. Corcept (CORT) hit $123.44, reporting $256M in Q2 revenue. Boundless Bio (BOLD) reached $3.02, initiating a first-in-human trial. Prelude (PRLD) peaked at $6.38, advancing JAK2V617F in Phase 1 trials.
3 min readJourney Medical (DERM) rose 13% on strong Q2 results, with revenue up 23% to $18.5M. Iovance (IOVA) gained 11% on 66% revenue growth to $99.3M. Caris (CAI) advanced 8% after raising 2026 revenue guidance to $1.03B-$1.04B. Prelude (PRLD) up 8% on narrower Q2 loss. Compugen (CGEN) gained 7% on COM701 trial progress. Conexeu (CNXU) rose 4% on regenerative aesthetics market opportunity.
3 min readPrelude Therapeutics (PRLD) reported Q2 2026 revenue of $5.7M and a net loss of $13.9M, or $0.14 per share. The company said it had $155.2M in cash and marketable securities as of June 30, 2026, projecting a runway into Q2 2028. R&D and G&A fell year over year. It also updated Phase 1 timelines for PRT13722 and PRT12396.
1 min readPrelude Therapeutics Inc (PRLD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter Presented
6 min readBiotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.
7 min readPrelude Therapeutics Inc (PRLD) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001678660 false 0001678660 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2
3 min read
